Mutations in IKK&ggr;

Details Mutations in IKK&ggr; Mutations in IKK&ggr;

2001-06-15

2004-02-10

Monshipouri, Maryam (Department: 1652)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S069100, C435S194000, C435S320100, C435S325000, C536S023200, C536S023100

Reexamination Certificate

active

06689564

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to compositions and methods involving IKK&ggr; and IKK&ggr; mutants. In particular, the present invention provides methods and compositions, including transgenic animals, suitable for use in determining means to treat, control, and/or prevent incontinentia pigmenti (IP). The present invention also provides methods to detect the presence of mutations in the IKK&ggr; gene and protein.
BACKGROUND OF THE INVENTION
Incontinentia pigmenti (IP), an X-linked human genodermatosis is a relatively rare disorder associated with multiple congenital defects (Landy and Donnai,
J. Med. Genet.
30:53-59 [1993]; and Francis and Sybert,
Semin. Cutan. Med. Surg.
16:54-60 [1997]), the gene of which (IP) has been mapped to Xq28 (Sefiani et al.,
Genomics
4:427-429 [1989]; and Sefiani et al.,
Human. Genet.
86:297-299 [1991]). Because of Lyonization, IP occurs almost exclusively in females, as most affected males die pre- and perinatally, unless their karyotype is 47XXY (Landy and Donnai, supra [1993]; Francis and Sybert, supra [1997]; and Scheuerle,
Am. J. Med. Genet.
77:201-218 [1998]). The characteristic features of IP are detected at or soon after birth. These features commonly begin with an erythematous eruption of the skin, with linear vesiculation. The blistering stage progresses to the verrucous stage, in which multiple longitudinal verrucous lesions are distributed along the skin. Within a year, these hyperkeratotic lesions disappear and leave behind the classic hyperpigmented whorls and streaks, which may fade later in life. The name of the disease is derived from the characteristic finding that these dark lines and swirls are due to loss (incontinence) of melanin from basal keratinocytes and its deposition as free pigment or within dermal macrophages (i.e., melanophages). The first three stages of the disease occasionally overlap. Eventually, many of the cutaneous symptoms disappear and the disease in adult females (i.e., subjects who can pass the disease along to their progeny) is characterized by irregular, pale, hairless, anhidrotic streaks and splashes of hyperpigmentation, resulting in a “marble cake” pattern (Wettke-Scahfer and Kantner,
Hum. Genet.
64:1-23 [1983]; Landy and Donnai, supra [1993]; and Francis and Sybert, supra [1997]).
Although this disease is rare, the significant morbidity and mortality associated with IP indicate the need to develop methods to treat and prevent the disease.
SUMMARY OF THE INVENTION
The present invention relates to compositions and methods involving both wild type and mutant I&kgr;B kinase-&ggr; (IKK&ggr;) genes and proteins. In particular, the present invention provides methods and compositions, including transgenic animals, suitable for use in determining means to treat, control, and/or prevent the genodermatosis, incontinentia pigmenti (IP).
IKK&ggr;, also known as the nuclear factor-&kgr;B (NF-&kgr;B) essential modulator or NEMO, is the essential regulatory subunit of the I&kgr;B kinase (IKK) and is encoded by an X-linked gene in mice and humans. It is required for NF-&kgr;B activation and resistance to tumor necrosis factor (TNF)-induced apoptosis. Female mice heterozygous for IKK&ggr;/NEMO deficiency develop unique dermatopathy, characterized by keratinocyte hyperproliferation, skin inflammation, hyperkeratosis, and increased apoptosis. Although Ikk&ggr;
+/−
females eventually recover, Ikk&ggr;
−
males die in utero. These symptoms and inheritance pattern are very similar to those of IP, a human genodermatosis that is syntenic with the IKK&ggr;/NEMO locus. Indeed, biopsies and cells from IP patients exhibit defective IKK&ggr;/NEMO expression, but normal expression of IKK catalytic subunits. This unique self-limiting disease, the first to be genetically linked to the IKK signaling pathway, is dependent upon X-chromosome inactivation. Although an understanding of the mechanism(s) is not necessary in order to use the present invention, the results obtained during the development of the present invention indicate that IKK&ggr;/NEMO-deficient cells trigger an inflammatory reaction that eventually leads to the death of these cells.
The present invention provides transgenic nonhuman animals having a genome comprising a disruption of the endogenous Ikk&ggr;/NEMO gene, which is a result of the insertion of a transgene and which causes a decrease in IKK&ggr;/NEMO expression. In some embodiments, IKK&ggr;/NEMO expression is eliminated. In a preferred embodiment, the transgenic nonhuman animal is a mouse bearing a heterozygous disruption of the Ikk&ggr;/NEMO gene. In some embodiments, the transgenic mouse exhibits hypersensitivity to TNF&agr;-induced apoptosis, while in other embodiments, the transgenic mouse exhibits dermatopathy, keratinocyte hyperproliferation, skin inflammation and/or hyperkeratosis.
The present invention further provides cells derived from a transgenic nonhuman animal having a genome comprising a disruption of the endogenous Ikk&ggr;/NEMO gene, wherein the disruption is a result of the insertion of a transgene. In particularly preferred embodiments, the disruption results in a decrease in IKK&ggr;/NEMO expression. In one preferred embodiment, the cell is derived from a transgenic mouse bearing a heterozygous disruption of the Ikk&ggr;/NEMO gene. In some embodiments, the cell is an embryonic stem cell, while in other embodiments, the cell is selected from the group consisting of embryonic fibroblasts, hepatocytes, thymocytes, splenocytes and epidermal cells. In some preferred embodiments, the cell exhibits hypersensitivity to TNF&agr;-induced apoptosis.
The present invention also provides methods for screening for biologically active agents to treat incontinentia pigmenti. These methods comprise: (a) exposing a transgenic mouse having a genome comprising a disruption of the endogenous Ikk&ggr;/NEMO gene, which is a result of the insertion of a transgene and which causes a decrease in IKK&ggr;/NEMO expression to a candidate agent; and (b) determining the effect of the candidate agent on incontinentia pigmenti pathology. In some embodiments, assessment of the effect of the candidate agent on incontinentia pigmenti pathology is accomplished by measuring sensitivity to TNF&agr;-induced apoptosis, while in other embodiments the degree of dermatopathy, keratinocyte hyperproliferation and/or skin inflammation is assessed.
The present invention also provides methods for detecting mutant Ikk&ggr;/NEMO genes in biopsy material obtained from individuals. These methods comprise detecting IKK&agr; and IKK&bgr; expression, in the absence of IKK&ggr;/NEMO expression. In some embodiments, detection is by immunoblot, while in others it is by Northern blot, Southern blot, reverse transcription-polymerase chain reaction (RT-PCR), single-stranded conformation polymorphism (SSCP) analysis and/or conformation-sensitive gel electrophoresis (CSGE).


REFERENCES:
patent: 4683195 (1987-07-01), Mullis
patent: 4683202 (1987-07-01), Mullis
patent: 4965188 (1990-10-01), Mullis
patent: 2003/0032055 (2003-02-01), Kenwrick et al.
Asea et al., “HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine,”Nat. Med. 6:435-442 [2000].
Ausubel et al. (eds.),Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York [1994]List of contents.
Barnes and Karin, “Nuclear factor-78 B—a pivotal transcription factor in chronic inflammatory diseases,”New Engl. J. Med. 336:1066-1071 [1997].
Beg et al., “Embryonic lethality and liver degeneration in mice lacking the RelA component of NK-&kgr;B,”Nature376:167-170 [1995].
Beg and Baltimore, “An essential role for NK-&kgr;B in preventing TNF-&agr;-induced cell death,”Science274:782-784 [1996].
Carney, “Incontinentia pigmenti: a world statistical analysis,”Arch. Dermatol. 112:535-542 [1976].
Chen et al., “Long-range sequ

Affiliated with

Also associated with

Rating

Mutations in IKK&ggr; does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mutations in IKK&ggr;, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutations in IKK&ggr; will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3326293